DEPRESSION PATENT FOR OROTATE APPROVED & GRANTED BY US PATENT OFFICE
SYDNEY, Oct. 11, 2021 (GLOBE NEWSWIRE) — Medlab Clinical LTD (ASX:MDC) is pleased to announce the Orotate patent, specifically to addressing depression in United States of America has been granted.
The United States Patent and Trademark Office (USPTO) has applied a Patent term to 28 MAY 2037 with a US patent number 11,135,181.
Previously Medlab announced [5 Jul 2021] final trial readouts for its phase 2 Depression trials.
Orotate use as a drug substance was key to the investigative product “NRGBiotic™”. The company has previously signalled that NRGBiotic™ will undertake improvements to simplify the formulation and ultimately that will make this treatment more affordable to patients and prescribers.
The Depression and the Orotate patent covers the following territories:
| • | United States | • | Europe | • | Hong Kong |
| • | Australia | • | New Zealand | ||
| • | Canada | • | Singapore |
Dr Sean Hall, CEO of Medlab said, “This is the second US patent approved in October. From a mental health perspective and within this global COVID-19 environment that is not subsiding, I think it’s safe to say we have the opportunity to be commercialising/developing this depression product in significant economies; Medlab’s ability to add genuine and novel outcomes, that are now protected, is key to our future commercial viability.”
Dr Hall added: “This patent is specific for treating depression or a depressive disorder that are not responding to anti-depressant medications (specifically SSRI use). So, what we now have is a patent covering 16 years for a commercially available substance to be used in one of the largest global health concerns of our time. Similar to the prior mentioned NanoCelle™ “Notice of Allowance” announcement [6 October 2021] I believe this will greatly enhance partnering prospects.”
ABOUT DEPRESSION
The World Health Organisation (WHO) state: “Depression is a common illness worldwide, with an estimated 3.8% of the population affected, including 5.0% among adults and 5.7% among adults older than 60 yearsi”.
Beyond Blue state: “A conservative three million Australians are living with anxiety or depression”ii.
ENDS
Authorisation & Additional information
This announcement was authorised by the Board of Directors of Medlab Clinical Limited.
About Medlab Clinical:
Medlab Clinical Ltd (ASX:MDC) is pioneering the development and commercialisation of a delivery platform, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability. Medlab’s pipeline comprises a number of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. Patented lead drug candidate NanaBis™ has been developed for cancer bone pain as a viable alternative to opioid use. Data to date, strongly suggests NanaBis™ may be equally effective in non-cancer neuropathic pain. NanoCelle®, the patented delivery platform is wholly owned by Medlab and developed in Medlab’s owned OGTR Registered Laboratory. NanoCelle® is designed to address known medication problems, addressing global unmet medical needs. Medlab operates in Australia (Head Office), USA, and the UK. For more information, please visit www.medlab.co
Medlab – better medicines, better patient care
| Medlab Clinical Mr Kerem Kaya, CFO T: +61 2 7201 0096 Kerem_kaya@medlab.co | Medlab US Investor Relations Laine Yonker lyonker@edisongroup.com |
i https://www.who.int/news-room/fact-sheets/detail/depression
iihttps://www.beyondblue.org.au/
